Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 3/20 | 0.52 |
| ▸ | PTGER2 | P43116 | 5/20 | 0.52 |
| ▸ | PTGER4 | P35408 | 4/20 | 0.52 |
| ▸ | PTGER3 | P43115 | 3/20 | 0.52 |
| ▸ | PTGIR | P43119 | 2/20 | 0.52 |
| ▸ | TBXA2R | P21731 | 2/20 | 0.52 |
| ▸ | PTGER1 | P34995 | 2/20 | 0.52 |
| ▸ | PTGFR | P43088 | 2/20 | 0.52 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.52 |
| ▸ | ESR1 | P03372 | 1/20 | 0.52 |
| ▸ | PGR | P06401 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.52 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | SLCO2A1 | Q92959 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16504094 | 1.00 | PTGDR2 (0.52) | PTGDR2PTGER2PTGER4PTGER3PTGIR | |
| SCHEMBL9127033 | 1.00 | PTGDR2 (0.52) | PTGDR2PTGER2PTGER4PTGER3PTGIR | |
| SCHEMBL15779590 | 0.97 | PTGER2 (0.49) | PTGDR2PTGER2PTGER4PTGER3PTGIR | |
| SCHEMBL12455951 | 0.97 | PTGER2 (0.49) | PTGDR2PTGER2PTGER4PTGER3PTGIR | |
| SCHEMBL7614717 | 0.96 | PTGER2 (0.49) | PTGDR2PTGER2PTGER4PTGER3PTGIR | |
| SCHEMBL8594912 | 0.96 | PTGER2 (0.49) | PTGDR2PTGER2PTGER4PTGER3PTGIR | |
| SCHEMBL7614725 | 0.96 | PTGER2 (0.49) | PTGDR2PTGER2PTGER4PTGER3PTGIR | |
| SCHEMBL8822956 | 0.95 | PTGDR2 (0.52) | PTGDR2PTGER2PTGER4PTGER3PTGIR | |
| SCHEMBL8822962 | 0.95 | PTGDR2 (0.52) | PTGDR2PTGER2PTGER4PTGER3PTGIR | |
| SCHEMBL9019869 | 0.93 | PTGDR2 (0.52) | PTGDR2PTGER2PTGER4PTGER3PTGIR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140235665-A1 | ANTI-CONSTIPATION COMPOSITION | SUCAMPO AG (CH) | 2014-08-21 | — | — | US | disclosed |
| US-20140235665-A1 | ANTI-CONSTIPATION COMPOSITION | SUCAMPO AG (CH) | 2014-08-21 | — | — | US | disclosed |
| US-8114890-B1 | Anti-constipation composition | SUCAMPO AG (CH) | 2012-02-14 | — | — | US | disclosed |
| US-20120022152-A1 | ANTI-CONSTIPATION COMPOSITION | SUCAMPO AG (CH) | 2012-01-26 | — | — | US | disclosed |
| US-8071613-B2 | Anti-constipation composition | SUCAMPO AG (CH) | 2011-12-06 | — | — | US | disclosed |
| US-5426115-A | Increasing blood stream rate in brain tissue | KABUSHIKIKAISHA UENO SEIYAKU OYO KENKYUJO (JP) | 1995-06-20 | — | — | US | disclosed |
| US-5290811-A | Administering as antiischemic or antiedema agent; brain disorders, cognition activators | KABUSHIKI KAISHA UENO SEIYAKU OYO KENKYUJO (JP) | 1994-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140235665-A1 | ANTI-CONSTIPATION COMPOSITION | SLC10A2, FABP6, VIP | PTGDR2 149/4885PTGER2 1121/4885PTGER4 1482/4885 |
| US-20120022152-A1 | ANTI-CONSTIPATION COMPOSITION | SLC10A2, FABP6, VIP | PTGDR2 188/4885PTGER2 1227/4885PTGER4 1640/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.